Sarepta Therapeutics, Inc. (SRPT)
Develops genetic medicines treating rare muscle diseases like Duchenne muscular dystrophy.
$15.43-0.03%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-3.0%
The outlook
SRPT is trading near its 52-week lows, well below its 50- and 200-day moving averages, reflecting weakness in recent price action. Analysts are mixed on the stock with a "Hold" consensus, though the average price target sits 44% above the current price. The elevated trailing P/E and bearish technical setup suggest investors remain cautious despite the gap between current price and analyst targets.
What’s behind the score
Analyst consensusHold — 2.7 avg of 23 analysts
Price trendBelow its 50- & 200-day averages
52-week range7% of the way from its 52-week low to high
Price targetAvg target +44% vs current price
Analyst price target
~12-month · 23 analysts$22.17average target+43.7% vs now
Now $15.43
Low $5.00High $38.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.63B
52-wk high
$25.32
52-wk low
$14.68
50-day avg
$17.11
200-day avg
$19.56
Trailing P/E
44.1